0
2019
Antifibrinolytic Drugs Market

Antifibrinolytic Drugs Market

by Indication (Gynecology, Hereditary Angiedema, Fibrinolytic Response Testing, Surgeries, and Others) and End user (Hospitals & Clinics, Ambulatory Surgical Centers, and Healthcare Specialty Process): Global Opportunity Analysis and Industry Forecast, 2019-2026
Update Available On-Demand

Report Code: A05914
Pages: 165
Dec 2019 | 5439 Views
Author(s) : Kavita Joshi , Onkar Sumant
Tables: 111
Charts: 34
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Antifibrinolytic Drugs Market

Request Now !

The global antifibrinolytic drugs market was valued at $13,593 million in 2018 and is expected to reach $19,333 million by 2026, registering a CAGR of 4.5% from 2019 to 2026. Antifibrinolytic drugs are used to prevent fibrinolysis or lysis of blood clots or thrombus. Fibrinolysis is a process in which stimulated plasminogen removes excess fibrin to promote fibrin clot formation and wound healing. Further, tissue plasminogen activators and other plasminogen activators are the first line mediators in lysis therapy. Blockers of fibrinolysis act when plasminogen is converted to plasmin, by reversely blocking the lysine binding sites of plasmin or by active inhibition of plasmin via serine protease inhibition. The antifibrinolytic drugs are widely used for inhibition of fibrinolysis and thus, are referred to as lysine analogues. The drugs are used to control massive hemorrhage and for other coagulation disorders. Moreover, antifibrinolytic agents are widely used in the management of mucosal bleeding where there is high fibrinolytic potential such as in oropharynx, nose, GI tract, and uterine-vaginal lining. In hemophilia, antifibrinolytic agents such as tranexamic acid or epsilon aminocaproic acid are generally used in the context of oral bleeding or dental surgery. Most common antifibrinolytic drugs used include tranexamic acid and ε-aminocaproic acid, and the serine protease inhibitor, aprotinin. 

Antifibrinolytics Drug Market

   

Significant rise in road accidents, accidental trauma, rise in medical surgeries, surge in incidence of angioedema, and growth in high-risk geriatric population across the globe are the major factors that drive the antifibrinolytic drugs market growth. For instance, trauma is the leading cause of mortality in people aged 1 to 65 years, according to the U.S. National Trauma Institute. In addition, as per the WHO, approximately 1.35 million people die each year as a result of road traffic crashes. Antifibrinolytic drugs play a vital role in averting clot lysis and thereby, loss of blood. Further, these drugs are also widely used to prevent heavy menstrual bleeding in women, also known as menorrhagia. These drugs are also used after surgeries such as cardiovascular surgeries and neurosurgeries to prevent enormous blood loss from patient’s body. Considerable surge in prevalence of bleeding disorders propel the antifibrinolytic drugs market growth. However, high cost of these drugs hamper the market growth. Furthermore, increase in research & development for developing novel innovative antifibrinolytic drugs is anticipated to create new opportunities for the market.

Global Antifibrinolytic Drugs Market Segmentation

The antifibrinolytic drugs market is segmented on the basis of indication, end-users, and region. On the basis of indication, it is classified into gynecology, hereditary angiedema, fibrinolytic response testing, surgeries, and others. By end user, it is divided into hospitals & clinics, ambulatory surgical centers, and healthcare specialty process. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Indication segment review

By indication, the gynecology segment accounted for majority of the antifibrinolytic drugs market share in 2018 and is expected to exhibit a prominent growth rate in the near future, owing to the increased adoption of these drugs to prevent menorrhagia i.e. heavy menstrual flow. Further, these drugs are manufactured to reduce bleeding by inhibiting endometrial clot-dissolving enzymes in the uterine lining. Tranexamic acid (TXA) is the most widely used drug for controlling menorrhagia.

Antifibrinolytic Drugs Market
By Indication

Your browser does not support the canvas element.

Surgeries segment is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

   

End user segment review

By end user, the hospitals & clinics segment dominated the antifibrinolytic drugs market in 2018 and is anticipated to maintain its dominance during the forecast period. This is attributed to the increased usage of these drugs in hospitals as most of the surgeries such as cardiovascular and neurosurgeries are performed in hospitals. However, the trauma centers segment is anticipated to grow at the fastest rate owing to the significant increase in road accidents across the globe. Road traffic injury death rates are highest in the African region. Even within high-income countries, people from lower socioeconomic backgrounds are more likely to be involved in road traffic crashes.

Antifibrinolytic Drugs Market
By End User

Your browser does not support the canvas element.

Trauma Centers is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

   

North America accounted for majority of the market share in 2018 and is anticipated to continue this trend during the forecast period. This is attributed to the increased adoption of these drugs by women to control heavy menstrual flow. Moreover, significant rise in surgeries in this region propels the market growth. For instance, in 2018, there were a total of 377,763 cardiovascular surgeries performed in North America. However, the Asia-Pacific region is anticipated to grow at the fastest rate during the forecast period, owing to surge in road accidents in this region. For instance, as per the WHO, more than 90% of road traffic deaths occur in low- and middle-income economies.

Antifibrinolytic Drugs Market
By Region

2026
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 6.1% during 2019-2026.

Get more information on this report : Request Sample Pages

   

Comprehensive competitive analysis and profiles of major market players such as Acic Fine Chems, Xanodyne Pharmaceuticals, Aurobindo Pharma Ltd., Akorn, Amerigen Pharms Ltd, Mylan, Pfizer (GenMed), Sanofi, Zydus Cadila, and Takeda are provided in this report.

Key Benefits for Stakeholders:

  • The antifibrinolytic drugs market share and analysis is based on a comprehensive analysis of key developments in the antifibrinolytic drugs industry.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the global market.
  • The study provides an in-depth analysis of the market trends to elucidate the imminent investment pockets.
  • The global antifibrinolytic drugs market trends are studied from 2018 to 2026.
  • Information about key drivers, restrains, and opportunities and their impact analysis on the market size is provided.
  • Porter’s five forces analysis illustrates the potency of buyers and suppliers operating in the industry.
  • The quantitative analysis of the global antifibrinolytic drugs market from 2019 to 2026 is provided to determine the market potential.

Antifibrinolytic Drugs Market Report Highlights

Aspects Details
By Indication
  • Gynecology
  • Hereditary Angiedema
  • Fibrinolytic Response Testing
  • Surgeries
  • Others
By End User
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Trauma Centers
By Region
  • North America  (U.S, Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Rest of Europe)
  • Asia Pacific  (Japan, China, India, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Akorn Inc., Aurobindo Pharma Limited, Bayer AG, Ferring Holding SA, Mylan N.V., Novartis International AG (Sandoz), Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vitruvias Therapeutics Inc.
 

Loading Table Of Content...


 
 

Antifibrinolytic drugs or agents are used in specific situations or in combination with clotting factor replacement to treat hemophilia. These prevent the breakdown of blood clots by counteracting chemicals in the mucous membrane. Antifibrinolytics are increasingly being used in operations associated with high risk of bleeding. These drugs are useful in the management of optimal coagulation. 

The antifibrinolytic drugs market is anticipated to witness a steady growth in the future, owing to its increased usage in patients suffering from hemophilia. In addition, surge in road accidents, accidental traumas, and medical surgeries further contribute to the market growth. However, high cost of these drugs and stringent reimbursement scenario is expected to hamper the growth in the future. Moreover, North America dominated the market in 2018, owing to the surge in cardiovascular surgeries and awareness among women toward usage of these drugs to prevent heavy menstrual flow. Asia-Pacific is anticipated to grow at the fastest rate in the future, owing to significant surge in the number of road accidents. 
 

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The market vaule of global Antifibrinolytic drugs market was $13,593 million in 2018.

A. The forecast period is from 2019 to 2026.

A. The market value of global Antifibrinolytic drugs market in 2019 is $1,4239 million.

A. The adoption of Antifibrinolytic drugs is expected to increase due to rise in its usage to by the females to control heavy menstrual flow.

A. No, the report does not provides value chain analysis.

A. Surge in road accidents across the globe is one of the majo factor boosting the market growth.

A. Emerging countries of Asia-Pacific region are growing at a growth% of 6.1%. India, and China are expected grow at a CAGR of 7.9% and 6.4% respectively.

A. The North America market held a major share in the Antifibrinolytic drugs market in 2018 and is expected to continue the trend in the forecasting period.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Free Sample

OR

Purchase Full Report of
Antifibrinolytic Drugs Market

Start reading instantly.
This Report and over 18,744+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Dec 2020 - Dec 2021)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Dec 2020 - Dec 2021)
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Dec 2020 - Dec 2021)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Dec 2020 - Dec 2021)
  • Enterprise
    License/PDF

  • $10,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Dec 2020 - Dec 2021)
  • Library
    Membership

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers